Ideas & Insights

UK government provides relief from DAC6, reducing the scope of reporting for UK intermediaries with cross-border transactions.

SPACs have grown in popularity recently as a means of going public. Learn why high-growth companies are using this method.

RSM helped Tanner Pharma overcome challenges with its NetSuite implementation provider, setting a foundation for growth and ongoing support.

What CFOs learned by going through a virtual IPO: hiring, roadshow planning and the process of getting vetted by an outside accounting firm.

After the US presidential election and looking ahead to a new year, most companies are still wondering when the world will return to normal.

Biden plans to expand Medicare, a move that the Congressional Budget Office estimates would cut drug spending by $450 billion over 10 years.

This recorded webcast gives an overview of how, when and why biopharma companies should invest in enterprise resource planning systems.

This webcast gives an overview of the top considerations for life sciences companies looking to repatriate or nearshore supply chains.

With the election approaching, RSM is looking at the economic stakes and the key issues for the life sciences industry.

We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.

For companies that may have dealt with a lab closure because of the pandemic, Scientist.com allows research to continue.

Amid the COVID-19 pandemic, life sciences companies, thrust in the spotlight, are positioned for strong growth.

Whether developing drug therapies, designing medical devices, or more, life sciences companies have complex technology needs.

The IRS updated taxpayers on its operations status and recognized the delays in processing check payments due on July 15, 2020.

Applications to sell unused state net operating losses and state research and development credits available the week of May 1, 2020.

Learn about opportunities for life sciences foreign direct investment (FDI) into the United States with this complimentary webcast.

An update on the economic impacts, kbusiness continuity strategies, and considerations from an audit, tax, VAT and supply chain perspective.

RSM professionals explain the parties involved and information needed for life sciences companies to comply with the federal law.

Here are some ways coronavirus could leave its mark on the global VAT, trade and tariff landscape for the life sciences industry.

The AICPA released the SOC for Supply Chain report to aid organizations with relevant controls to address business risk.